Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL15-TransDC in Advanced Solid Tumors
NCT05964361Phase 2Completed
- Start
- Dec 2023
- Primary completion
- Sep 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of interleukin-15-transpresenting Wilms tumor 1-targeting dendritic cell vaccine in esophageal cancer, pancreatic cancer (PC), ovarian cancer, liver cancer. Started Dec 2023; status: completed.
02
Drugs
interleukin-15-transpresenting Wilms tumor 1-targeting dendritic cell vaccine
03
Conditions
esophageal cancerpancreatic cancer (PC)ovarian cancerliver cancer
Beyond the preview
Go deeper on NCT05964361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964361.